Phase1, Open-Label, Dose Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
Latest Information Update: 18 May 2021
At a glance
- Drugs SM 04755 (Primary)
- Indications Colorectal cancer; Gastric cancer; Liver cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Biosplice Therapeutics
Most Recent Events
- 05 Sep 2018 Status changed from suspended to completed.
- 21 Sep 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 23 Jul 2014 New trial record